News

Fierce Pharma1d
Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Novo Nordisk Forges Multiple Partnerships To Sell Obesity Drug Wegovy At A Discount
The pharmaceutical firm Novo Nordisk is pursuing a multipronged strategy to regain market share that it has lost to Eli Lilly ...
NJBIZ1d
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
The Economist21h
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...
Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Wegovy Deal Makes Cofounder Of Hair Loss Pill Seller Hims A Billionaire
Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...
Novo Nordisk Guidance in Focus Amid Stagnant Prescription Trends -- Earnings Preview
--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...